Synthetic cathinone abuse

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue , 2013, Pages 109-115

  Capriola, Michael ^a  

^a Thomasville Medical Center   (United States)

Author keywords

Alkaloids poisoning; Designer drugs chemistry; Street drugs pharmacology; Substance related disorders epidemiology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; AMPHETAMINE; CATHINONE; CATHINONE DERIVATIVE; COCAINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DOPAMINE; METHYLONE; NORADRENALIN; NOREPHEDRINE; NORPSEUDOEPHEDRINE; SEROTONIN; UNCLASSIFIED DRUG;

AGGRESSION; AGITATION; ANGINA PECTORIS; ANOREXIA; BEHAVIOR DISORDER; BRUXISM; CHEMICAL STRUCTURE; DELUSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ABSORPTION; DRUG ABUSE; DRUG EXCRETION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRAFFIC; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; INTRINSIC SYMPATHOMIMETIC ACTIVITY; IRRITABILITY; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; NEUROTOXICITY; NONHUMAN; PARANOIA; PARANOID PSYCHOSIS; PARKINSONISM; POISON CENTER; PSYCHOSIS; REVIEW; SELF REPORT; TACHYCARDIA; URINARY EXCRETION; VIOLENCE;

EID: 84879756491     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S42832     Document Type: Review

References (70)

1. US Department of Justice National Drug Intelligence Center. Situation report: Synthetic cathinones (bath salts)-an emerging domestic threat. 2011. Available from: http://www.justice.gov/archive/ndic/pubs44/44571/44571p.pdf. Accessed December 10, 2012.
2. Kalix P, Braenden O. Pharmacological aspects of the chewing of khat leaves. Pharmacol Rev. 1985;37(2):149-164.
3. [No authors listed]. Review of the pharmacology of khat. Report of a WHO advisory group. Bull Narc. 1980;32(3):83-93.
4. Szendrei K. The chemistry of khat. Bull Narc. 1980;32(3):5-35.
5. United Nations. Studies on the chemical composition of khat. III. Investigations on the phenylalkylamine fraction. UN document MNAR/11/1975.
6. Peterson DW, Maitai CK, Sparber SB. Relative potencies of two phe-nylalkylamines found in the abused plant Catha edulis, khat. Life Sci. 1980;27(22):2143-2147.
7. Berrang BD, Lewin AH, Carroll FI. Enantiomeric alpha-aminopropiophenones (cathinone): preparation and investigation. J Org Chem. 1982;47(13):2643-2647.
8. Luqman W, Danowski TS. The use of khat (Catha edulis) in Yemen. Social and medical observations. Ann Intern Med. 1976;85(2):246-249.
9. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM. 2010;103(11):875-879.
10. Kelly JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal. 2011;3(7-8):439-453.
11. Glennon RA, Young R, Martin BR, Dal Cason TA. Methcathione ("cat"): an enantiomeric potency comparison. Pharmacol Biochem Behav. 1995;50(4):601-606.
12. Galvan-Arzate S, Santamaria A. Neurotoxicity of diethylpropion: neurochemical and behavioral findings in rats. Ann N Y Acad Sci. 2002;965:214-224.
13. Gardos G, Cole JO. Evaluation of pyrovalerone in chronically fatigued volunteers. Curr Ther Res Clin Exp. 1971;13(10):631-635.
14. Advisory Council on the Misuse of Drugs. ACMD report on the consideration of the cathinones. 2010. Available from: http://www.homeoffce. gov.uk/acmd1/acmd-cathinodes-report-2010?view=Binary. Accessed November 1, 2012.
15. Coppola M, Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food." Toxicol Lett. 2012;211(2):144-149.
16. James D, Adams RD, Spears R, et al. Clinical characteristics of mephed-rone toxicity reported to the UK National Poisons Information Service. Emerg Med J. 2011;28(8):686-689.
17. Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing fephedrone and MDPV with serum, urine, and product quantifcation. J Med Toxicol. 2012;8(3):310-313.
18. Centers for Disease Control and Prevention (CDC). Emergency department visits after use of a drug sold as "bath salts"-Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep. 2011;60(19): 624-627.
19. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confrmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol. 2011;49(6):499-505.
20. Dick D, Torrance C. Mixmag drugs survey. Mixmag. 2010;225: 44-53.
21. American Association of Poison Control Centers (AAPCC). Bath salts data. 2012. Available from: https://aapcc.s3.amazonaws.com/fles/library/Bath_Salts_Data_for_Website_1.09.2013.pdf. Accessed December 15, 2012.
22. Drug Enforcement Administration. Special Report: Synthetic Can-nabinoids and Synthetic Cathinones Reported in NFLIS, 2009-2010. Springfeld (VA): DEA; 2011. Available from: http://www.deadiversion. usdoj.gov/nfis/2010rx_synth.pdf. Accessed December 10, 2012.
23. Dargan PI, Sedefov R, Gallegos A, Wood DM. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal. 2011;3(7-8):454-463.
24. Regan L, Mitchelson M, Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg Med J. 2011;28(12): 1055-1058.
25. Drug Enforcement Administration. Schedules of controlled substances: placement of ezogabine into Schedule V. Final rule. Fed Regist. 2011;76(241):77895-77899.
26. Kalix P. Cathinone, a natural amphetamine. Pharmacol Toxicol. 1992; 70(2):77-86.
27. Toennes S W, Harder S, Schramm M, Niess C, Kauert GF. Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. Br J Clin Pharmacol. 2003;56(1):125-130.
28. Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU. Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin Pharmacol Ther. 1994;55(5):556-562.
29. Brenneisen R, Fisch HU, Koelbing U, Geisshusler S, Kalix P. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol. 1990;30(6):825-828.
30. Guantai AN, Maitai CK. Metabolism of cathinone to d-norpseudoephed-rine in humans. J Pharm Sci. 1983;72(10):1217-1218.
31. Toennes S W, Kauert G F. Excretion and detection of cathinone, cathine, and phenylpropanolamine in urine after kath chewing. Clin Chem. 2002;48(10):1715-1719.
32. Kalix P. Pharmacological properties of the stimulant khat. Pharmacol Ther. 1990;48(3):397-416.
33. Meyer MR, Wilhelm J, Peters FT, Maurer HH. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxi-cological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioana Chem. 2010;397(3):1225-1233.
34. Zaitsu K, Katagi M, Kamata HT, et al. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int. 2009;188(1-3):131-139.
35. Kamata HT, Shima N, Zaitsu K, et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica. 2006;36(8):709-723.
36. Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom. 2010;45(12):1426-1442.
37. Meyer MR, Vollmar C, Schwaninger AE, Wolf E, Maurer HH. New cathinone-derived designer drugs 3-bromomethcathinone and 3-fuoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. J Mass Spectrom. 2012;47(2):253-262.
38. Khreit OI, Grant MH, Zhang T, Henderson C, Watson DG, Sutcliffe OB. Elucidation of the phase I and phase II metabolic pathways of (+/-)-4'-methylmethcathinone (4-MMC) and (+/-)-4'-(trifuoromethyl) methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS(2). J Pharm Biomed Anal. 2013;72:177-185.
39. Pawlik E, Plässer G, Mahler H, Daldrup T. Studies on the phase I metabolism of the new designer drug 3-fuoromethcathinone using rabbit liver slices. Int J Legal Med. 2012;126(2):231-240.
40. Mueller DM, Rentsch KM. Generation of metabolites by an automated online metabolism method using human liver microsomes with subsequent identifcation by LC-MS(n), and metabolism of 11 cathinones. Anal Bioanal Chem. 2012;402(6):2141-2151.
41. Psychonaut WebMapping Research Group. Mephedrone Report. London: Institute of Psychiatry, King's College London; 2009.
42. Newcombe R. Mephedrone: The Use of Mephedrone (M-cat, Meow) in Middlesbrough. Manchester: Lifeline Publications and Research; 2009.
43. Gibbons S, Zloh M. An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett. 2010;20(14):4135-4139.
44. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168(2):458-470.
45. Cozzi NV, Sievert MK, Shulgin AT, Jacob P. 3rd, Ruoho AE. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol. 1999;381(1):63-69.
46. Lopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J. Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol. 2012;167(2):407-420.
47. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2011;28(4):280-282.
48. Kehr J, Ichinose F, Yoshitake S, et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol. 2011;164(8):1949-1958.
49. Davies S, Wood DM, Smith G, et al. Purchasing 'legal highs' on the Internet-is there consistency in what you get? QJM. 2010;103(7): 489-493.
50. European Monitoring Centre for Drugs and Drug Addiction. Report on the Risk Assessment of Mephedrone in the framework of the Council Decision on New Psychoactive Substances. Lisbon: EMCDDA; 2011.
51. Sauer C, Hoffmann K, Schimmel U, Peters FT. Acute poisoning involving the pyrrolidinophenone-type designer drug 4'-methyl-alpha-pyrrolidinohexanophenone (MPHP). Forensic Sci Int. 2011;208(1-3): e20-e25.
52. Brunt TM, Poortman A, Niesink RJ, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol. 2011;25(11):1543-1547.
53. Al-Motarreb A, Briancon S, Al-Jaber N, et al. Khat chewing is a risk factor for acute myocardial infarction: a case-control study. Br J Clin Pharmacol. 2005;59(5):574-581.
54. Balint EE, Falkay G, Balint GA. Khat-a controversial plant. Wien Klin Wochenschr. 2009;121(19-20):604-614.
55. Forrester MB. Synthetic cathinone exposures reported to Texas poison centers. Am J Drug Alcohol Abuse. 2012;38(6):609-615.
56. Borek HA, Holstege C P. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Ann Emerg Medicine. 2012;60(1):103-105.
57. Sammler EM, Foley PL, Lauder GD, Wilson SJ, Goudie AR, O'Riordan JI. A harmless high? Lancet. 2010;376(9742):742.
58. Iqbal M, Monaghan T, Redmond J. Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report. J Med Case Rep. 2012;6(1):52.
59. Yildirim EA, Eşsizoǧlu A, Köksal A, Doǧu B, Baybas' S, Gökalp P. [Chronic manganese intoxication due to methcathinone (ephedron) abuse: a case report]. Turk Psikiyatri Derg. 2009;20(3):294-298. Turkish.
60. Ellison G. Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retrofexus, implying the loss of forebrain control circuitry. Eur Neuropsychopharmacol. 2002; 12(4):287-297.
61. Puerta E, Hervias I, Aguirre N. On the mechanisms underlying 3,4-methylenedioxymethamphetamine toxicity: the dilemma of the chicken and the egg. Neuropsychobiology. 2009;60(3-4):119-129.
62. den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanpera I, Korpi ER. Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone. Pharmacol Biochem Behav. 2012;103(3):501-509.
63. Mixmag. Mixmag's drug survey: the results. 2012. Available from: http://www.mixmag.net/drugssurvey. Accessed December 1, 2012.
64. Van Hout MC, Bingham T. "A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy. 2012;23(3):188-197.
65. Wood DM, Davies S, Greene SL, et al. Case series of individuals with analytically confrmed acute mephedrone toxicity. Clin Toxicol. 2010;48(9):924-927.
66. Pearson JM, Hargraves TL, Hair LS, et al. Three fatal intoxications due to methylone. J Anal Toxicol. 2012;36(6):444-451.
67. Adamowicz P, Tokarczyk B, Stanaszek R, Slopianka M. Fatal mephed-rone intoxication-a case report. J Anal Toxicol. 2013;37(1):37-42.
68. Wood DM, Davies S, Puchnarewicz M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sym-pathomimetic toxicity. J Med Toxicol. 2010;6(3):327-330.
69. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug "bath salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol. 2012;8(1):69-75.
70. Derungs A, Schietzel S, Meyer MR, Maurer HH, Krahenbuhl S, Liechti ME. Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin Toxicol. 2011;49(7):691-693.